We hope that you can join us for the December MTCONS Supplemental Meeting on Thursday, December 15, 2022 at E3 Chophouse, Nashville, TN.
The topic is Balversa (erdafitinib) The 1st FDA-approved treatment for metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations that has progressed after first-line chemotherapy
The program is hosted by Michael Ragland, Janssen Pharmaceuticals, Inc.
PROGRAM FACULTY:
Kent Shih, MD
Medical Oncologist Tennessee Oncology, PLLC, Nashville, TN
Consultant is a paid speaker for Janssen Pharmaceuticals, Inc.
Date/Time:
Thursday, December 15, 2022
Registration 5:30 PM CT
Presentation – 6:00 PM CT
VENUE:
E3 Chophouse
1628 21st Avenue South
Nashville, TN
